Topoisomerase IIα gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer

Journal of Clinical Oncology

Volumn 24, Issue 16, 2006, Pages 2409-2411

  Buzdar, Aman U ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; AROMATASE INHIBITOR; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; THIOTEPA; TRASTUZUMAB; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN; TUMOR MARKER;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; EDITORIAL; GENE AMPLIFICATION; GENE DELETION; GENE LOCATION; GENE OVEREXPRESSION; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; ENZYMOLOGY; FEMALE; GENETICS; NOTE; TREATMENT OUTCOME;

ANTHRACYCLINES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; HUMANS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33744991353     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.05.9113     Document Type: Editorial

References (28)

1. Tanner M, Isola J, Wiklund T, et al: Topoisomerase IIa gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu amplified breast cancer. Results from the randomized trial SBG 9401. J Clin Oncol 24:2428-2438, 2006
2. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681-1692, 1988
3. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential Paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:963-964, 2003
4. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005
5. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
6. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
7. Buzdar AU, Marcus C, Smith TL, et al: Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55:2761-2765, 1985
8. Jarvinen TA, Tanner M, Rantanen V, et al: Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156:839-847, 2000
9. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
10. Jarvinen TA, Tanner M, Barlund M, et al: Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26:142-150, 1999
11. Coon JS, Marcus E, Gupta-Burt S, et al: Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 8:1061-1067, 2002
12. Thor AD, Berry DA, Budman DR, et al: ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346-1360, 1998
13. Ravdin PM, Green S, Albain KS, et al: Initial report of the SWOG biological correlative study of c-erb B-2 expression as a predictor of outcome in a trial comparing adjuvant CAFT with tamoxifen alone. Proc Am Soc Clin Oncol 17:97a, 1998
14. Paik S, Bryant J, Park C, et al: ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998
15. Pegram MD, Finn RS, Arzoo K, et al: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-547, 1997
16. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
17. Durbecq V, Desmed C, Paesmans M, et al: Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol 25:1473-1479, 2004
18. Tsai-Pflugfelder M, Liu LF, Liu AA, et al: Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A 85:7177-7181, 1988
19. Knoop AS, Knudsen H, Balslev E, et al: Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23:7483-7490, 2005
20. Champoux JJ: DNA topoisomerases: Structure, function, and mechanism. Annu Rev Biochem 70:369-413, 2001
21. Bhargava R, Lai P, Chen B: HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: Chromogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol 123:889-895, 2005
22. Villman K, Stahl E, Liljegren G, et al: Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas. Mod Pathol 15:486-491, 2002
23. Barrett-Lee PJ: Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: A review of chemotherapy. Endocr Relat Cancer 12:S125-S133, 2005 (suppl 1)
24. Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC -> T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC -> TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94:S5, 2005 (suppl 1)
25. Arpino G, Ciocca DR, Weiss H, et al: Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 92:69-75, 2005
26. Jarvinen TA, Liu ET: HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat 78:299-311, 2003
27. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
28. Buzdar AU, Hortobagyi GN, Kau SW, et al: Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. J Clin Oncol 10:1540-1546, 1992